# JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

> **NCT07384377** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 123 (estimated)

## Conditions studied

- HER2-positive Colorectal Cancer

## Interventions

- **DRUG:** JSKN003
- **DRUG:** Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.

## Key facts

- **NCT ID:** NCT07384377
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-06-15
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07384377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07384377, "JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07384377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*